Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
IPO Date: September 1, 2014
Sector: Healthcare
Industry: Biotech
Market Cap: $1.06B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.23 | 2.74%
Avg Daily Range (30 D): $0.13 | 1.65%
Avg Daily Range (90 D): $0.15 | 1.81%
Institutional Daily Volume
Avg Daily Volume: 1.74M
Avg Daily Volume (30 D): 1.12M
Avg Daily Volume (90 D): 1.21M
Trade Size
Avg Trade Size (Sh.): 173
Avg Trade Size (Sh.) (30 D): 101
Avg Trade Size (Sh.) (90 D): 102
Institutional Trades
Total Inst.Trades: 2,246
Avg Inst. Trade: $1.22M
Avg Inst. Trade (30 D): $1.37M
Avg Inst. Trade (90 D): $1.09M
Avg Inst. Trade Volume: .11M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $1.29M
Avg Closing Trade (30 D): $1.02M
Avg Closing Trade (90 D): $1M
Avg Closing Volume: 127.56K
       
News
Jan 8, 2025 @ 8:35 PM
New American College of Rheumatology Guidelines fo...
Source: Spherix Global Insights
Oct 2, 2024 @ 1:48 PM
Corporate and Individual Donations Provide Much-Ne...
Source: American Kidney Fund
Jun 17, 2024 @ 8:46 AM
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump...
Source: Zacks Equity Research
May 7, 2024 @ 1:55 PM
How Much Upside is Left in Aurinia (AUPH)? Wall St...
Source: Zacks Equity Research
May 2, 2024 @ 11:10 AM
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, To...
Source: Zacks Equity Research
Financials
  TTM Q3 2024 Q2 2024
Basic EPS $-.16 $.1 $.01
Diluted EPS $-.16 $.1 $.01
Revenue $ 220.36M $ 67.77M $ 57.19M
Gross Profit $ 192.27M $ 61.74M $ 48.28M
Net Income / Loss $ -22.55M $ 14.35M $ .72M
Operating Income / Loss $ -32.69M $ 11.75M $ -1.51M
Cost of Revenue $ 28.09M $ 6.04M $ 8.91M
Net Cash Flow $ -9.26M $ 3.74M $ -31.05M
PE Ratio    
Splits
Oct 23, 2013:   50:1